Skip to main content
Clinical Trials/ISRCTN45877994
ISRCTN45877994
Completed
未知

Early Surgery versus optimal Current step-up prActice for chronic PancrEatitis (ESCAPE): a multi-centre randomised controlled trial

Academic Medical Centre Amsterdam (Netherlands)0 sites88 target enrollmentMarch 25, 2011

Overview

Phase
未知
Intervention
Not specified
Conditions
Chronic pancreatitis
Sponsor
Academic Medical Centre Amsterdam (Netherlands)
Enrollment
88
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Registry
who.int
Start Date
March 25, 2011
End Date
July 1, 2017
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Academic Medical Centre Amsterdam (Netherlands)

Eligibility Criteria

Inclusion Criteria

  • Registration criteria:
  • 1\. Age 18 years
  • 2\. Confirmed chronic pancreatitis: according to the M\-ANNHEIM diagnostic criteria
  • 3\. Dilated pancreatic duct \[5 mm, established by magnetic resonance cholangiopancreatography (MRCP), Computerised Tomography (CT) or Endoscopic ultrasound (EUS)], with or without enlargement of the pancreatic head
  • 4\. Presence of moderate, non\-debilitating pain. This will be defined as chronic abdominal pain (present for at least 3 months) sufficiently relieved with non\-opioid analgesics
  • Randomisation criteria (after fulfilling inclusion criteria for registration):
  • 1\. Need for upgrade from non\-opioids to opioid analgesics: newly developed need for opioids analgesics (opioids needed at least 3 days per week) and persistently needed for at least 2 weeks in a row
  • 2\. Informed consent for randomisation

Exclusion Criteria

  • 1\. History of prolonged need of opioids for chronic pancreatitis for a period over 2 months in the last 2 years
  • 2\. Previous pancreatic surgery
  • 3\. Previous endoscopic dilatation or stenting of the pancreatic duct
  • 4\. Episode of biliary obstruction in the last 2 months (defined as jaundice or bilirubine levels 25 micromol / L) or the presence of a stent in the common bile duct (CBD)
  • 5\. Proven autoimmune pancreatitis (including elevated levels of gamma\-globulins (IgG))
  • 6\. Suspected or established pancreatic malignancies
  • 7\. Life expectancy of \< 1 year for any reason
  • 8\. Presence of duodenal obstruction necessitating surgery, as judged by the expert panel
  • 9\. Presence of a pseudocyst larger than 6 cm necessitating intervention, as judged by the expert panel
  • 10\. Contra\-indications for surgery, always evaluated by the expert panel (e.g. American Society of Anesthesiology class IV, severe portal hypertension due to occluded portal vein)

Outcomes

Primary Outcomes

Not specified

Similar Trials